PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the pricing of its initial public offering of 9,375,000 shares of...
Evommune Announces Pricing of its Initial Public Offering
Seeking Alpha / 3 hours ago 1 Views
Comments